ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018
M
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 80 citations in OpenAlex.
- An Acetylcholine M1 Receptor-Positive Allosteric Modulator (TAK-071) in Parkinson Disease With Cognitive Impairment: A Phase 2 Randomized Clinical Trial.JAMA neurology · 2025Trial
- Trial
- Article
- Gestodene Accelerates Cutaneous Wound Healing via PAR1-Selective Positive Allosteric Modulation.International journal of molecular sciences · 2026Article
- Article
- Discovery of VU6052254: A Novel, Potent MACS chemical neuroscience · 2025Article
- Synthesis of Azaisoindolinones by Heterogeneous Catalyzed Regioselective Hydrodeoxygenation ofACS sustainable chemistry & engineering · 2025Article
- Discovery of a Novel spACS medicinal chemistry letters · 2025Article
- Application of Deuterium in an MACS chemical neuroscience · 2025Article
- Control of cortical slow oscillations and epileptiform discharges with photoswitchable type 1 muscarinic ligands.PNAS nexus · 2025Article
- Discovery of VU0467319: an MACS chemical neuroscience · 2025Article
- Cholinergic System Structure and Function Changes in Individuals with Down Syndrome During the Development of Alzheimer's Disease.Current topics in behavioral neurosciences · 2025Review
- Anticholinergic drugs for parkinsonism and other movement disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- A golden age of muscarinic acetylcholine receptor modulation in neurological diseases.Nature reviews. Drug discovery · 2024Review
- Discovery of VU6007496: Challenges in the Development of an MACS chemical neuroscience · 2024Article
- Analysing the effect caused by increasing the molecular volume in M1-AChR receptor agonists and antagonists: a structural and computational study.RSC advances · 2024Article
- Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials.Brain sciences · 2024Review
- The Partial MACS chemical neuroscience · 2023Article
- MProceedings of the National Academy of Sciences of the United States of America · 2023Article
- MScience signaling · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Highly selective positive allosteric modulators (PAMs) of the M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.